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Abstract
Campylobacter jejuni is a major food-borne pathogen and a common causative agent of human enterocolitis.
Fluoroquinolones are a key class of antibiotics prescribed for clinical treatment of enteric infections including
campylobacteriosis, but fluoroquinolone-resistant Campylobacter readily emerges under the antibiotic selection pressure.
To understand the mechanisms involved in the development of fluoroquinolone-resistant Campylobacter, we compared the
gene expression profiles of C. jejuni in the presence and absence of ciprofloxacin using DNA microarray. Our analysis
revealed that multiple genes showed significant changes in expression in the presence of a suprainhibitory concentration of
ciprofloxacin. Most importantly, ciprofloxacin induced the expression of mfd, which encodes a transcription-repair coupling
factor involved in strand-specific DNA repair. Mutation of the mfd gene resulted in an approximately 100-fold reduction in
the rate of spontaneous mutation to ciprofloxacin resistance, while overexpression of mfd elevated the mutation frequency.
In addition, loss of mfd in C. jejuni significantly reduced the development of fluoroquinolone-resistant Campylobacter in
culture media or chickens treated with fluoroquinolones. These findings indicate that Mfd is important for the development
of fluoroquinolone resistance in Campylobacter, reveal a previously unrecognized function of Mfd in promoting mutation
frequencies, and identify a potential molecular target for reducing the emergence of fluoroquinolone-resistant
Campylobacter.
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Introduction
Campylobacter jejuni, a Gram-negative microaerobic bacterium, is
one of the most prevalent bacterial foodborne pathogens in
humans, causing more than 2 million cases of diarrhea each year
in the U.S. alone [1,2,3]. As an enteric pathogen, this organism
causes watery diarrhea and/or hemorrhagic colitis. Campylobacter
infection is also the most common antecedent to Guillain-Barre
syndrome, an acute flaccid paralysis that may lead to respiratory
muscle compromise and death [4,5]. In developed countries,
person-to-person transmission of Campylobacter is rare, and the
main source of human Campylobacter infections is via food, water, or
milk contaminated by Campylobacter [6].
Fluoroquinolone (FQ) antimicrobials are often prescribed for
clinical treatment of diarrhea caused by enteric bacterial
pathogens including Campylobacter [7,8]. However, Campylobacter
is increasingly resistant to FQ antimicrobials, which has become
a major concern for public health [9,10,11]. FQ-resistant (FQ
R)
Campylobacter developed in food producing animals can be
transmitted to humans via the food chain. Poultry are
considered the major reservoir for C. jejuni and a significant
source for FQ
R Campylobacter infections in humans, because the
majority of domestically acquired cases of human campylobac-
teriosis result from consumption of undercooked chicken or food
contaminated by raw chicken [2,12,13]. Although FQ antimi-
crobials have been banned since 2005 in poultry production in
the U.S., FQ
R Campylobacter continue to persist on poultry farms
[14,15,16].
The main targets of FQs in bacteria are DNA gyrases and/or
topoisomerase IV [17,18]. In Campylobacter, the resistance to FQ
antimicrobials is mediated by point mutation in the quinolone
resistance-determining region (QRDR) of gyrA in conjunction with
the function of the multidrug efflux pump CmeABC
[10,19,20,21]. Acquisition of high-level FQ resistance in Campylo-
bacter does not require stepwise accumulation of point mutations in
gyrA. Instead, a single point mutation in gyrA can lead to clinically
relevant levels of resistance to FQ antimicrobials [19,20,22].
Specific mutations at positions Thr-86, Asp-90 and Ala-70 in
GyrA have been linked to FQ resistance in C. jejuni [10,19]. When
enumerated by ciprofloxacin (CIPRO)-containing plates, sponta-
neous FQ
R Campylobacter mutants occur at a frequency as high as
10
26 [23], suggesting that C. jejuni possess a high mutation rate to
FQ resistance. CmeABC, an energy-dependent efflux system,
contributes significantly to the intrinsic and acquired resistance to
FQs in C. jejuni by reducing the accumulation of the antibiotics
within Campylobacter cells [19,20,24,25]. The expression level of
cmeABC also influences the frequencies of emergence of spontane-
ous FQ
R mutants [23].
One unique feature of FQ resistance development in Campylo-
bacter is the rapid emergence of FQ
R mutants from a FQ-
susceptible population when treated with FQ antimicrobials. This
has been observed in Campylobacter-infected animals or patients
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FQ-susceptible Campylobacter, treatment with enrofloxacin resulted
in the emergence of FQ
R Campylobacter mutants that were detected
in feces within 24–48 hours after the initiation of treatment, and
the FQ
R population continued to expand during the treatment
and eventually occupied the intestinal tract at a density as high as
10
7 CFU/g feces [19,29,30]. As shown in a comparison study, the
same FQ treatment did not result in the development and
enrichment of FQ
R E. coli in chickens [29], suggesting that C. jejuni
has a unique ability to adapt to FQ treatment. This high frequency
of emergence of FQ
R Campylobacter mutants in response to the
selection pressure may have directly contributed to the global
prevalence of FQ
R Campylobacter. For example, multiple studies
have shown the temporal link between the approval of FQ
antimicrobials for use in animal production and the rapid increase
of FQ
R Campylobacter isolates from both animals and humans
[9,31,32,33,34,35,36,37,38,39]. In some regions of the world, the
vast majority of Campylobacter isolates have become resistant to FQ
antimicrobials [22,40,41].
The rapidness and magnitude of FQ resistance development in
Campylobacter in response to FQ treatment suggest that both
selective enrichment of pre-existing spontaneous mutants and
adaptive gene expression may contribute to the emergence of FQ
R
Campylobacter, but how Campylobacter responds to FQ treatment is
unknown. Within bacterial cells, FQ antimicrobials form a stable
complex with gyrases and DNA, which generates double-stranded
breaks in DNA and leads to bacterial death [18]. In other bacteria,
antibiotic treatments (including FQs) induce the SOS response,
which upregulates multiple genes involved in DNA repair,
recombination, and mutation as well as other functions
[42,43,44,45]. The SOS response is controlled by LexA, a
transcriptional repressor. DNA damage triggers LexA autoclea-
vage, which derepresses the SOS genes controlled by LexA. Once
activated, SOS response promotes the development of drug
resistance, horizontal transfer of genetic materials, and production
of virulence factors [45,46,47]. Unlike many other bacterial
organisms, epsilonproteobacteria including Campylobacter and Helicobac-
ter don’t have a LexA ortholog [46] and also lack many genes
involved in DNA repair, recombination, and mutagenesis, such as
the mutHL genes (methyl-directed mismatch repair), the umuCD
genes (UV-induced mutagenesis), and SOS-controlled error-prone
DNA polymerases [48,49,50]. These observations suggest that
Campylobacter may not have the typical SOS response system. In
light of this possibility, it is intriguing to determine how
Campylobacter copes with FQ treatment and what facilitates the
emergence of FQ
R mutants in Campylobacter.
In this study, we examined the gene expression profiles of C.
jejuni NCTC 11168 in response to treatment with CIPRO.
Consistent with the prediction, a typical SOS response was not
observed in Campylobacter treated with CIPRO. However, 45 genes
showed $1.5-fold (p,0.05) changes in expression when Campylo-
bacter was exposed to a suprainhibitory dose of CIPRO for 30 min.
One of the up-regulated genes was mfd (mutation frequency
decline), which encodes a transcription-repair coupling factor
involved in DNA repair. The mfd gene in E. coli was originally
linked to the phenotype of mutation frequency decline [51,52].
Subsequently it was found that Mfd functions as a transcription-
repair coupling factor and promotes strand-specific DNA repair
[53,54]. DNA lesions stall RNA polymerase during transcription.
Mfd displaces the stalled RNA polymerase from the DNA lesions
in an ATP-dependent manner, recruits the UvrABC excinuclease
complex, and enhances the repair of the DNA lesions on the
transcribed strand [54,55]. Thus, Mfd couples transcription with
DNA repair and contributes to mutation frequency decline.
Recently it was reported that depending on the nature of DNA
damage and the availability of NTPs, Mfd can also promote the
forward translocation of arrested RNA polymerase in the absence
of repair, leading to transcriptional bypass of non-repaired lesions
[55]. In contrast to its previously known function in the decline of
mutation frequency in other bacterial organisms [51,52], Mfd in
Campylobacter was found to promote the emergence of spontaneous
FQ
R mutants and the development of FQ
R mutants under FQ
treatments in this study. These findings define a novel function of
Mfd and significantly improve our understanding of the molecular
mechanisms underlying the development of FQ
R Campylobacter.
Results
Transcriptional analysis of C. jejuni response to FQ
treatment
To understand the adaptive response of Campylobacter to FQ
treatment, DNA microarray was used to analyze the transcrip-
tional changes in C. jejuni NCTC 11168 after exposure to CIPRO.
When the Campylobacter cells were treated with a subinhibitory
concentration (0.06 mg/ml; 0.56 the MIC) of CIPRO for
1.5 hours, no genes showed $1.5-fold changes in expression,
suggesting that the transcriptional response to the low dose of
CIPRO was very limited. When the Campylobacter cells were
treated with a suprainhibitory concentration (1.25 mg/ml; 106the
MIC) of CIPRO for 30 min, 45 genes showed $1.5-fold (p,0.05)
changes in expression (Table 1), among which 13 were up-
regulated and 32 were down-regulated. The up-regulated genes
are involved in cell membrane biosynthesis, cellular processes, and
transcription-coupled DNA repair or have unknown functions,
while the majority of the down-regulated genes are involved in
energy metabolisms (Table 1). Consistent with the lack of LexA,
the core genes involved in SOS responses in other bacteria, such as
recA, uvrA, ruvC, ruvA, and ruvB, did not show significant changes in
expression. The expression of other genes involved in DNA repair
and recombination also did not change significantly. These
findings indicate that C. jejuni does not mount a typical SOS
response or upregulate the general DNA repair system in the early
response to CIPRO treatment. Notably, cj1085c, a homolog of mfd,
was upregulated in the presence of CIPRO. Two up-regulated
Author Summary
As a food-borne bacterial pathogen, Campylobacter jejuni
is a common causative agent of gastrointestinal illnesses in
humans. Development of antibiotic resistance in Campylo-
bacter, especially to fluoroquinolone (a broad-spectrum
antimicrobial), compromises clinical treatments and pre-
sents a major public health threat. It is not well understood
why Campylobacter is highly adaptable to fluoroquinolone
treatment or how it acquires mutations associated with
fluoroquinolone resistance. Understanding the molecular
mechanisms involved in the resistance development will
help us to reduce the emergence of fluoroquinolone-
resistant Campylobacter. Using DNA microarray and other
molecular methods, as well as animal studies, we
uncovered the key role of Mfd in promoting spontaneous
mutations and development of fluoroquinolone resistance
in Campylobacter. Mfd is a transcription-repair coupling
factor involved in DNA repair and was not previously
known for its role in promoting mutations conferring
antibiotic resistance. Our findings not only reveal a novel
function of Mfd, but also provide a potential molecular
target for reducing the emergence of fluoroquinolone-
resistant Campylobacter.
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Gene ID and Functional Category P-Value Q-Value n-Fold change
Microarray qRT-PCR
Cell membrane
Cj0205 uppP, undecaprenyl-diphosphatase 0.0135 0.130143 1.59 6.1
Cj0735 putative periplasmic protein 0.0186 0.14811 1.70 NT*
Cj0824 uppS, undecaprenyl diphosphate synthase 0.0099 0.120356 1.52 2.1
Cj1351 pldA, phospholipase A 0.0046 0.094812 2.02 2
Cj0033 putative integral membrane protein 0.0033 0.086471 21.52 NT
Cj0179 exbB1, biopolymer transport protein 0.0412 0.217646 21.88 NT
Cj0486 putative sugar transporter 0.0043 0.091967 21.57 NT
Cj0553 putative integral membrane protein 0.0106 0.121714 21.59 NT
Cj0834c ankyrin repeat-containing possible periplasmic protein 0.0089 0.110719 21.51 NT
Cj1013c putative cytochrome C biogenesis protein 0.0058 0.096095 21.52 NT
Cj1662 putative integral membrane protein 0.0055 0.096095 21.68 NT
Cj1663 putative ABC transport system ATP-binding protein 0.0002 0.067622 21.75 NT
DNA replication, recombination and repair
Cj1085c mfd, transcription-repair coupling factor 0.0029 0.082832 1.57 2.2
Cj0718 dnaE, DNA polymerase III, alpha chain 4.07E-05 0.052459 21.62 21.98
Cellular process and energy metabolism
Cj0041 putative flagellar hook-length control protein 0.0357 0.204764 1.93 NT
Cj0065c folk, putative 2-amino-4-hydroxy-6-
hydroxymethyldihydropteridine pyrophosphokinase
0.0117 0.129371 1.54 NT
Cj1030c lepA, GTP-binding protein homolog 0.0057 0.210454 1.54 NT
Cj1280c putative ribosomal pseudouridine synthase 0.0252 0.170564 1.50 NT
Cj0009 gltd, glutamate synthase (NADPH) small subunit 0.0007 0.067622 21.74 NT
Cj0123c putative tRNA-dihydrouridine synthase 0.0020 0.076881 21.87 22.1
Cj0227 argD, acetylornithine aminotransferase 0.0208 0.151677 21.69 NT
Cj0283c cheW, chemotaxis protein 0.0125 0.130143 21.52 NT
Cj0415 putative GMC oxidoreductase subunit 0.0191 0.148174 21.53 NT
Cj0490- ald, putative aldehyde dehydrogenase C-terminus 0.0013 0.076653 21.80 NT
Cj0537 oorb, OORB subunit of 2-oxoglutarate:acceptor
oxidoreductase
0.0024 0.076881 21.67 22.23
Cj0734c hisJ, histidine-binding protein precursor 0.0404 0.214389 21.59 NT
Cj0764c speA, biosynthetic arginine decarboxylase 0.0116 0.129371 21.97 21.96
Cj0767c kdtB,3-deoxy-D-manno-octulosonic-acid transferase 0.0370 0.207688 21.58 NT
Cj1264c hydD, putative hydrogenase maturation protease 0.0009 0.067622 22.13 26.7
Cj1265c hydC, Ni/Fe-hydrogenase B-type cytochrome subunit 0.0016 0.076881 22.12 NT
Cj1266c hydB, Ni/Fe-hydrogenase large subunit 0.0032 0.086244 21.56 NT
Cj1364c fumC, fumarate hydratase 0.0255 0.171473 21.52 NT
Cj1476c pyruvate-flavodoxin oxidoreductase 0.0133 0.130143 21.55 NT
Cj1566c nuoN, NADH dehydrogenase I chain N 0.0039 0.088549 22.03 22.71
Cj1567c nuoM, NADH dehydrogenase I chain M 0.0055 0.096095 21.60 NT
Cj1624c sdaA, L-serine dehydratase 0.0046 0.094812 21.58 NT
Cj1682c gltA, citrate synthase 0.0167 0.142007 21.54 NT
Cj1688c secY, preprotein translocase subunit 0.0021 0.076881 21.63 22.15
Cj1717c leuC, 3-isopropylmalate dehydratase large subunit 0.0018 0.076881 21.61 NT
Unknown function
Cj0163c hypothetical protein 0.0204 0.151393 1.60 NT
Cj0814 hypothetical protein 0.0002 0.067622 1.99 NT
Cj0959c hypothetical protein 0.0233 0.160562 1.50 NT
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production [56,57], while pldA encodes an outer membrane
phospholipase that has been implicated in hemolysis, capsular
production, and virulence [58,59]. According to the Q values, the
identified genes would have an estimated false discovery rate
(FDR) of 20%. However, quantitative real-time RT-RCR (qRT-
PCR) confirmed all of the 11 genes selected from the microarray
list (Table 1), suggesting that the actual FDR is lower than the
estimation.
Characteristics of Mfd
Cj1085c (978aa) was annotated as Mfd [48] and shows 31.5%
aminoacididentitytotheE.coliMfdprotein(1148aa).Inaddition,it
contains the characteristic domains conserved in Mfd proteins, such
as the ATP/GTP-binding site motif and the superfamily II helicase
motif.Mfdinotherbacteriahasbeenshowntobeinvolvedinstrand-
specific DNA repair by displacing lesion-stalled RNA polymerase
and recruiting enzymes involved in recombination events [54,60].
The mfd locus is highly conserved inCampylobacter and is present inall
Campylobacter species and C. jejuni strains that have been sequenced to
date. The Mfd proteins in different Campylobacter species share 57–
79% identity to the Mfd in C. jejuni NCTC 11168. Within C. jejuni,
the Mfd proteins are 98–100% homologous among different strains.
The mfd gene is located in the middle of a gene cluster, whose
transcription is in the same direction (partially shown in Fig. 1A).
The downstream gene Cj1084c encodes a putative ATP/GTP
binding protein, while the upstream gene Cj1086c encode a
hypothetical protein [48]. It is unknown if mfd and its flanking genes
form an operon, but it appeared that Cj1086c and mfd were co-
transcribed because a RT-PCR product spanning both ORFs was
amplified (data not shown).
Expression levels of mfd influence the frequency of
emergence of spontaneous FQ-resistant mutants
Since mfd was the only DNA repair related gene that showed a
significant change in expression in the early response of C. jejuni to
CIPRO treatment (Table 1), we examined its role in the
emergence of spontaneous FQ
R mutants in Campylobacter. Firstly,
the mfd gene was inactivated by insertional mutagenesis (Fig. 1B).
As shown in Fig. 2, the mfd mutant (JH01) showed a approximately
Gene ID and Functional Category P-Value Q-Value n-Fold change
Microarray qRT-PCR
Cj1025c hypothetical protein 0.0389 0.210454 1.54 NT
Cj0125c hypothetical protein Cj0125c 0.0031 0.084482 21.53 NT
Cj0554 hypothetical protein 0.0083 0.107589 21.71 NT
*NT: Not tested.
doi:10.1371/journal.ppat.1000083.t001
Table 1. Cont.
Figure 1. Insertional mutation of mfd and its impact on the
transcription of cj1084c. (A) Diagram depicting the genomic
organization of mfd and its flanking regions. ORFs and their directions
of transcription are indicated by boxed arrows. The location of the
inserted kanamycin resistance gene (aphA3)i nmfd is indicated. (B) PCR
confirmation of the aphA3 insertion into the mfd gene in JH01. Lane 1
shows the PCR product from 11168, while Lane 2 shows the PCR
product of JH01. The primers used in the PCR were mfd-F2 and mfd-R2.
Lane M contains 1 kb DNA size markers (Promega). (C) RT-PCR analysis
of cj1084c expression in strains 11168 and JH01. The same amount of
total RNA from 11168 (Lane 1) and JH01 (Lane 2 and 3) were used as
template in the RT-PCR. Lanes 1 and 2 are normal RT-PCR reactions.
Lane 3 is a RT-PCR reaction without reverse transcriptase (DNA-free
control for the RNA preparation). In Lane 4, genomic DNA of 11168 was
used as template (positive control for PCR).
doi:10.1371/journal.ppat.1000083.g001
Figure 2. Frequencies of emergence of spontaneous FQ
R
mutants in different C. jejuni strains including the wild-type
11168, the mfd mutant (JH01), the complemented mfd mutant
(JH02), and the mfd-overexpressing construct (JH03). Three
different concentrations of CIPRO (1, 2, and 4 mg/ml, respectively) were
used in the detection plates to count FQ
R colonies. Each bar represents
the mean6standard deviation of frequencies from three independent
cultures. The bars labeled with different letters indicate that they are
significantly different (P,0.05).
doi:10.1371/journal.ppat.1000083.g002
Fluoroquinolone Resistance in Campylobacter
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FQ
R mutants detected using plates containing three different
concentrations (1, 2, and 4 mg/ml, respectively) of CIPRO.
Complementation of the mfd mutant in trans by a plasmid-carried
mfd restored the frequencies of mutant emergence to the wild-type
level (JH02 in Fig. 2). As determined by qRT-PCR, the expression
level of mfd in the complemented construct (JH02) was fully
restored (1.76 the wild-type level). pRY112 alone (without the
cloned mfd gene) did not complement the mfd mutant in the
mutation frequency (data not shown). These results indicate that
Mfd contributes significantly to the rate of spontaneous mutations
to FQ resistance.
Secondly, we determined if the enhanced expression of mfd
increases the mutation frequency. For this purpose, we
constructed strain JH03, which was a wild-type 11168 strain
containing an extra copy of mfd carried on a shuttle plasmid. In
JH03, the mRNA of mfd increased 3.8 times compared with that
in 11168 as determined by qRT-PCR. When compared with the
wild-type 11168, the frequency of emergence of FQ
R mutants
from JH03 increased about 10-fold (Fig. 2). The increase was
reproducible in multiple experiments and was statistically
significant (P,0.05). These results indicated that overexpression
of mfd increases the frequency of emergence of spontaneous FQ
R
mutants.
Given that there is only one nucleotide between the mfd gene
and its downstream gene cj1084c, it was prudent to determine if
the mfd mutation resulted in a polar effect on the expression of
cj1084c. RT–PCR showed that cj1084c was transcribed at a
comparable level in both the mfd mutant and the wild-type
NCTC 11168 (Fig. 1C). RT-PCR was also performed using 10-
fold serial dilutions of the RNA template, which yielded
comparable results between the two strains (data not shown).
PCR without the reverse transcriptase did not yield a product
(Fig. 1C), indicating that the mRNA templates had no DNA
contamination. These results suggested that the insertional
mutation in the mfd gene did not cause an apparent polar effect
on expression of the downstream gene. This finding plus the
complementation data (Fig. 2) strongly indicate that loss of Mfd
is responsible for the observed reduction in the mutation
frequency in JH01.
Loss of mfd does not affect the susceptibility of C. jejuni
to antibiotics
To examine if the reduction in the emergence of spontaneous
FQ
R mutants is caused by the increased susceptibility of the mfd
mutant to CIPRO, we compared the MICs of several antibiotics in
the mfd mutant with those in the wild type. Our results did not
reveal any differences between the mutant and the wild type in
their susceptibility to the tested antibiotics including erythromycin,
ampicillin, streptomycin, and CIPRO (data not shown). In
addition, there was no apparent difference in growth kinetics
between the wild-type and the mfd mutant either in MH broth
(without antibiotics) or in MH broth supplemented with a
subinhibitory concentration (0.06 mg/ml) of CIPRO (Fig. 3).
The growth rates of the mfd over-expressing strain (JH03) and the
complemented mutant (JH02) were also similar to that of the wild
type (Fig. 3). Thus, the reduced spontaneous mutation rate to FQ
resistance in the mfd mutant was not attributable to decreased
growth rate or increased susceptibility to antibiotics. In addition,
the CIPRO-resistant colonies examined for gyrA mutations all
carried the C257T mutation in gyrA and had a CIPRO MIC of
.32 mg/ml regardless of the backgrounds (11168 or JH01) from
which the mutants were selected.
Mfd contributes to the emergence of FQ
R Campylobacter
under in vitro treatment
FQ
R Campylobacter mutants emerge rapidly from a FQ-susceptible
populationoncetreatedwithFQantimicrobials[19,26,27,28,29,30].
To determine if Mfd influences the development of FQ
R
Campylobacter under selection pressure, we conducted inv i t r ogrowth
experiments, in which C. jejuni was treated with a suprainhibitory
concentrations of CIPRO (4 mg/ml). In the first treatment
experiment, 10
9 CFU of bacterial cells were inoculated into each
flaskcontaining100 mlMHbrothwith4 mg/mlofCIPRO,yielding
an initial cell density of 10
7 CFU/ml. At the beginning of the
treatment, 1–3 CFU/ml of FQ
R mutants were detected in the flasks
inoculated with 11168, while no FQ
R mutants were detected in the
cultures inoculated with JH01 (Fig. 4A). One day after the initiation
of the treatment, the numbers of FQ
R mutants in the 11168 cultures
grew to a level ranging from a few hundreds to a few thousands
Figure 3. Growth kinetics of various C. jejuni constructs in culture media. The strains were grown in MH broth (A) or MH broth
supplemented with 0.06 mg/ml of CIPRO (B).
doi:10.1371/journal.ppat.1000083.g003
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R mutants
were detected in the cultures of JH01 (Fig. 4A). The FQ
R
populations expanded on day 2 in both strains, but the FQ
R
population of JH01 was still about 1,000-fold less than that of 11168.
Due to the continued enrichment of the FQ
R mutants by CIPRO
and the fact that the mutants of 11168 was entering the stationary
phase, the average difference between 11168 and JH01 on day 3
decreased, but was still more than one order of magnitude (Fig. 4A).
In the second experiment, 2610
7 CFU bacterial cells of 11168 or
JH01 were inoculated into each flask containing 20 ml of MH broth
with 4 mg/mlofCIPRO,yielding an initial celldensityof 10
6 CFU/
ml. At the beginning of the treatment, no FQ
R mutants were
detected from either 11168 or JH01 (Fig. 4B). On day 1 after the
initiation of the treatment, FQ
R Campylobacter emerged from some of
the cultures of 11168 and continued to expand in numbers on day 2
and day 3.Incontraryto 11168, noFQ
R mutants emerged from any
ofthe JH01 cultures during the three-day incubation (Fig. 4B). In the
third experiment, the inoculum was decreased to 2610
4 CFU per
flask (initial cell density=10
3 CFU/ml), and no FQ
R mutants were
detected from either 11168 or JH01 after three day’s incubation
(data not shown). These results indicated that emergence of FQ
R
mutants under treatment with CIPRO was influenced by the initial
bacterial cell density and facilitated by the function of Mfd.
Mfd affects the emergence of FQ
R mutants in vivo
To determine if Mfd influences the emergence of FQ
R
Campylobacter during in vivo therapeutic treatment, broiler chickens
were infected with 11168 or JH01 and then treated with
enrofloxacin administered in drinking water (50 ppm). The birds
in both groups were quickly colonized by C. jejuni after inoculation
(Fig. 5). Before the treatment with enrofloxacin, all birds were
colonized by Campylobacter and the colonization levels (CFU/g
feces) were similar in both groups (p.0.05). One day after
initiation of the treatment, the number of colonized chickens and
the levels of colonization decreased drastically in both groups, with
Campylobacter detectable only in three chickens that were inoculated
with the wild-type strain (Fig. 5A). After that, the numbers of
Campylobacter in both groups rebounded. On day 3 after the
initiation of the treatment, all of the birds in the 11168 group were
re-colonized by Campylobacter and remained colonized until the end
of the experiment. For the group inoculated with JH01, 6 of the11
birds became positive with Campylobacter on day 3 after initiation of
the treatment (Fig. 5A) and 3 birds remained negative until the end
of the experiment. On days 3, 5 and 7 after initiation of the
treatment, the average colonization level of the JH01-inoculated
group was approximately 3 log units lower than that of the 11168-
inoculated group (Fig. 5A) and the differences were statistically
significant (p,0.05). The number of FQ
R Campylobacter in each
chicken was also monitored. Prior to the treatment, no FQ
R C.
jejuni was detected in any of the chickens (Fig. 5B). On day 1 after
initiation of the treatment, the three Campylobacter-positive birds of
the 11168-inoculated group still carried FQ-susceptible Campylo-
bacter. However, FQ
R C. jejuni appeared on day 3 in all birds of the
11168-inoculated group and in some birds of the JH01-inoculated
group (Fig. 5B). Comparison of the total Campylobacter counts
(Fig. 5A) with the numbers of FQ
R Campylobacter (Fig. 5B) revealed
that the birds were re-colonized by FQ
R mutants after initiation of
the treatment. The average numbers of FQ
R Campylobacter in the
JH01-inoculated group were approximately 3 log units lower that
those of the 11168-inoculated group (Fig. 5B) and the differences
were statistically significant (p,0.05). These results indicate that
loss of Mfd significantly reduced the rates of emergence of FQ
R
Campylobacter in enrofloxacin-treated chickens.
Representative Campylobacter isolates obtained at different
sampling times from both groups were tested for CIPRO MICs
using E-test strips. The result showed that before treatment all the
tested isolates from both groups were susceptible to CIPRO
(MICs=0.094–0.125 mg/ml). The majority of the tested isolates
from day 1 after initiation of the treatment were still susceptible to
CIPRO (MICs=0.094–0.5 mg/ml). On day 3 after the initiation
of treatment, 21 of the 22 tested isolates (from both groups) had a
CIPRO MIC of .32 mg/ml and the other one had an MIC of
8 mg/ml. Similarly, the majority (44 out of 49) of the tested isolates
from days 5 and 7 had a CIPRO MIC of .32 mg/ml and the rest
had MICs from 1–24 mg/ml. The MIC results further confirmed
the differential plating results that the chickens were re-colonized
by FQ
R Campylobacter.
Discussion
When Campylobacter cells were treated with a subinhibitory
concentration (0.06 mg/ml, 0.56 the MIC) of CIPRO for
Figure 4. Development of FQ
R mutants from 11168 (solid
circle) and JH01 (triangle) grown in MH broth supplemented
with 4 mg/ml of CIPRO. In (A), the initial cell density (at time 0) of
each culture was 10
7 CFU/ml, while in (B) the initial cell density was
10
6 CFU/ml. Each symbol represents the number of FQ
R mutants in a
single culture. Each horizontal bar represents the mean log10 CFU/ml
from each strain at a given time. (A) Displays the results of 3
independent experiments, while (B) represents the results of two
independents experiments. The detection limit of the plating method is
1 CFU/ml.
doi:10.1371/journal.ppat.1000083.g004
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using the cut-off criteria defined in this study. This result was
somewhat similar to the study with Haemophilius influenzae [61] in
that the treatment with a low concentration of CIPRO induced
few changes in gene expression, but was different from that study
because several genes involved in SOS response were upregulated
in Haemophilius influenzae. Prolonged treatment of Campylobacter with
the subinhibitory concentration of CIPRO may reveal noticeable
changes in gene expression, but culturing Campylobacter with
0.06 mg/ml of CIPRO reduces its growth rate (Fig. 3), which will
make the comparison with the non-treated control unfeasible and
complicate the interpretation of the microarray results. To mimic
clinical treatment, C. jejuni cells were exposed to a suprainhibitory
dose (1.25 mg/ml, 106the MIC) of CIPRO. This dose is within
the concentration range of CIPRO in gut contents during FQ
treatment in chickens [62]. The reason that we treated the samples
for 0.5 hour instead of a longer time was to detect the primary
response triggered by CIPRO, instead of the secondary response
caused by cell death. When Campylobacter cells were treated with
this suprainhibitory dose for 0.5 hour, the expression of multiple
genes was significantly altered (Table 1). Notably, the majority of
the affected genes were downregulated and many of them are
involved in cellular processes and energy metabolism (Table 1).
This result is similar to the findings obtained with other bacteria
[43,44,61] and supports the notion that reducing cellular
metabolism is a common strategy utilized by bacteria to cope
with antibiotic treatment.
Within bacterial cells CIPRO interacts with gyrase and DNA,
blocking DNA replication and transcription [18]. When exposed to
CIPRO, the expression of gyrA and gyrB in various bacteria was
either altered or unchanged [43,61,63]. In this study, we found that
the expression of gyrA, gyrB,a n dtopA was not significantly affected in
Figure 5. Development of FQ
R Campylobacter mutants in chickens initially infected with FQ-susceptible Campylobacter, but treated
with enrofloxacin. (A) The level of total Campylobacter in each chicken inoculated with the wild-type 11168 (open circle) or the mfd mutant strain
(JH01; solid circle). The treatment with enrofloxacin started on day 0 and lasted for five consecutive days (indicated by a bracket on top of the panel).
(B) The level of FQ
R Campylobacter in each chicken inoculated with the wild-type (open circle) or the mfd mutant (solid circle). In both panels, each
symbol represents the number of Campylobacter in a single bird. Each group includes eleven chickens and the mean of each group at a given time is
indicated by a horizontal bar. A chicken is considered negative if the level of colonization was below the detection limit (10
2 CFU/ g of feces).
doi:10.1371/journal.ppat.1000083.g005
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encoding enzymes involved in DNA repair, recombination, or
mutagenesis, such as recA, ruvABC, uvrABC,a n dmutS,d i dn o tc h a n g e
significantly. Only two genes involved in DNA metabolism (mfd and
dnaE) were affected by CIPRO under the conditions used in this
study (Table 1). Theses observations indicate that C. jejuni does not
mount a typical SOS response under the treatment with FQ. These
findings are also consistent with the fact that C. jejuni lacks LexA, the
key regulator of bacterial SOS responses [46].
In addition to transcription-coupled DNA repair, Mfd has been
associated with other functions in bacteria [64]. For example, Mfd
of Bacillus subtilis is involved in homologous DNA recombination
and stationary-phase mutagenesis [65,66]. Inactivation of the mfd
gene of B. subtilis resulted in a great reduction in the number of
prototrophic revertants to Met
+, His
+, and Leu
+ during starvation
[66], indicating that Mfd promotes adaptive mutagenesis. This
finding is in contrast to the known function of Mfd in mediating
mutation frequency decline and could be explained by the role of
Mfd in promoting transcriptional bypass and consequently
increasing the adaptive mutagenesis rates [66].
In this study we found that Mfd increases the frequency of
emergence of spontaneous FQ
R mutants in Campylobacter (Fig. 2).
Furthermore, the mfd mutation also decreased the frequency of
emergence of spontaneous streptomycin-resistant mutants in
Campylobacter (data not shown). Together, the results convincingly
showed that Mfd is an important player in modulating the
mutation rates in Campylobacter. To our knowledge, this is the first
report documenting the key role of Mfd in promoting spontaneous
mutation rates in a bacterial organism. How Mfd contributes to
the increased mutation rates in Campylobacter is unknown, but it can
be speculated that transcriptional bypass mediated by Mfd may
actively occur in replicating non-stressed Campylobacter populations,
resulting in an elevated level of retromutagenesis (fixed changes in
DNA sequence due to transcriptional mutation [67]) that
contributes to the size of the mutant pools. This possibility
remains to be examined in future studies. Although mfd contributes
significantly to the mutation rate (Fig. 2), its expression level was
not precisely proportional to the mutation frequencies. For
example, expression of mfd was upregulated 3.8-fold in JH03,
but its mutation frequency increased 10-fold. This difference is
probably due to the fact that emergence of spontaneous mutants is
a multi-step process and Mfd only contributes to one of the steps in
the process. It is also possible that Mfd interacts with other
proteins in modulating the mutation frequency. Thus, the changes
in mfd expression level and the mutation frequency are not exactly
at the same scale.
Another interesting observation of this study is the upregulation
of mfd by CIPRO. The enhanced expression may be needed for
transcription repair because CIPRO treatment causes DNA
damage, which stalls RNA polymerase. Alternatively, the
increased production of Mfd may enhance transcriptional bypass
of the non-repaired DNA lesions in order to maintain cell viability
and/or promote mutations for resistance. This possibility is high
given the facts that massive DNA damage incurred by a
suprainhibitory dose of CIPRO may overwhelm the DNA repair
system and Campylobacter must maintain certain levels of transcrip-
tion to survive the treatment, that Mfd contributes significantly to
the mutation rates to FQ resistance (Fig. 2), and that Campylobacter
does not have the error-prone DNA polymerases, such as Pol II,
Pol IV, and Pol V [48]. E. coli and other bacteria have these error-
prone DNA polymerases [68,69], which are repressed by LexA,
but upregulated by the SOS response triggered by DNA damage.
Once produced, the enzymes perform translesion DNA synthesis,
allowing replication to continue without DNA repair. This special
functional feature results in reduced genetic fidelity, but allows for
bacterial survival under stress. The outcome of the enhanced
expression of the error-prone enzymes is the increased mutation
rates, which contribute to the emergence of drug resistance [70].
In the absence of a SOS response and the error-prone DNA
polymerases, Campylobacter may use Mfd as an alternative pathway
to increase mutation rates. Thus, enhanced expression of mfd may
represent an adaptive response of Campylobacter to the stresses
imposed by CIPRO treatment. How CIPRO upregulates
Campylobacter Mfd is unknown and further work in this direction
is warranted.
FQ
R Campylobacter readily emerges from a FQ-susceptible
population when treated with FQ antimicrobials (Figs. 4 and 5).
As shown in the in vitro experiment, the development of FQ
R
population under CIPRO treatment is influenced by the initial cell
density (Fig. 4 and the corresponding text) as well as the functional
state of Mfd. Considering the differences in spontaneous mutation
rate between 11168 and JH01 (Fig. 2), it was likely that the 11168
and JH01 inocula had different numbers of pre-existing FQ
R
mutants, which were selected by CIPRO and contributed to the
differences in the FQ
R population detected in the cultures of the two
strains. The inoculum-dependent emergence of FQ
R mutants in
both 11168 and JH01 suggests that development of FQ
R
Campylobacter under FQ treatment involves selection of preexisting
mutants. However, the magnitude and dynamics of FQ
R develop-
ment can not be totally explained by selection. For example, in some
cultures FQ
R mutants were not detectible until the 2
nd day of the
incubation (Fig. 4). A single mutant at time zero in a culture flask
would grow to a population of more than 2,000 cells in one day (the
generation time of C. jejuni in MH broth is about 2 hours), which
would be readily detected by the plating method on day 1. Thus, if
selection was the only factor in the development of FQ
R
Campylobacter, the latest time for detecting the pre-existing mutants
in the mutant-positive flasks would be day 1 after initiation of the
treatment. Obviously, this was not the case for all of the cultures
becausesomeofthem did not showFQ
R mutantsuntil day 2 (Fig. 4).
In addition, some cultures were negative with FQ
R mutants at time
zero, but showed a large number of mutants at day 1, which could
not be easily explained by sole selection of a few preexisting mutants
from the inocula. Considering these unexplainable observations and
the factthat a small fraction oftheFQ-susceptible inoculum survived
the killing effect as long as one day after the initiation of the
treatment (data not shown), it was possible that new FQ
R mutants
were developed during the treatment. If this occurs, Mfd may
enhance the emergence of new mutants by promoting transcrip-
tional bypass or other mechanisms, which may partly explain the
differences between 11168 and JH01 in the dynamics of emergence
ofFQ
Rmutants.Thus,thereisapossibilitythatbothselectionofpre-
existing mutants and de nova formation of mutants are involved in
the development of FQ
R Campylobacter during treatment with FQ
antimicrobials.
The role of Mfd in the development of FQ
R mutants was
further shown by the in vivo experiment, in which Campylobacter-
infected chickens were treated with enrofloxacin (Fig. 5). Previous
studies have shown that therapeutic use of FQ antimicrobials in
chickens promotes the emergence of FQ
R Campylobacter
[19,27,28,29,30], which can be potentially transmitted to humans
via the food chain. In this study, we showed that inactivation of mfd
significantly reduced the development of FQ
R Campylobacter in
chickens (Fig. 5). In fact, several birds in the JH01-inoculated
group became negative with Campylobacter once the treatment was
initiated. Since the mfd mutant did not show a growth defect in vitro
(Fig. 3) and colonized chickens as efficiently as the wild-type strain
(see the colonization level before treatment in Fig. 5), the observed
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R mutants were not due to
changes in growth characteristics. These in vivo results (Fig. 5) plus
the in vitro findings (Fig. 4) clearly showed that Mfd plays an
important role in the development of FQ
R Campylobacter mutants
under the selection pressure. To our knowledge, this is the first
report that documents the role of Mfd in the development of FQ
resistance in a bacterial pathogen. Since Mfd is highly conserved
in bacterial organisms [64], it would be interesting to know if this
finding applies to other bacterial pathogens. In addition, inhibition
of Mfd functions may represent a feasible approach to reducing
the emergence of FQ
R Campylobacter.
Materials and Methods
Bacterial strains and growth conditions
C. jejuni strain NCTC 11168 (ATCC 700819) was used in this
study. The strain was routinely grown in Mueller-Hinton (MH)
broth (Difco) or on MH agar at 42uC under microaerobic
conditions (5% O2, 10% CO2, and 85% N2). The media were
supplemented with kanamycin (50 mg/ml) or chloramphenicol
(4 mg/ml) as needed. Escherichia coli cells were grown at 37uC with
shaking at 200 r.p.m. in Luria Bertani (LB) medium which was
supplemented with ampicillin (100 mg/ml) or kanamycin (30 mg/
ml) when needed.
DNA microarray and qRT-PCR
DNA microarray was used to identify genes that were
differentially expressed in C. jejuni 11168 treated with CIPRO.
For RNA isolation, Campylobacter cells were grown for 24 hours to
the mid exponential phase (OD600<0.1,0.15) and split into two
equal portions, one of which was treated with CIPRO and the
other served as a non-treated control. A subinhibitory concentra-
tion (0.06 mg/ml, 0.56 the MIC) and a suprainhibitory dose
(1.25 mg/ml, 106 the MIC) of CIPRO were used in the
treatments. For the treatment with 0.06 mg/ml of CIPRO, the
treated and non-treated samples were incubated at 42uC for
1.5 hours under microaerobic conditions, while for the treatment
with 1.25 mg/ml of CIPRO, the samples were incubated at 42uC
for 30 min under microaerobic conditions. Immediately after the
incubation, RNAprotect Bacteria Reagent (Qiagen, Valencia, CA)
was added to the cultures to stabilize mRNA. The total RNA from
each sample was extracted using the RNeasy Mini Kit (Qiagen).
The purified RNA samples were treated with On-Column DNase
Digestion Kit (Qiagen) followed by further treatments with DNase
to remove residual DNA contamination. RNA samples were
extracted from 6 independent treatments with each concentration
of CIPRO. Absence of contaminating DNA in the RNA samples
was confirmed by RT-PCR. The concentration of total RNA was
estimated with the NanoDrop ND-1000 spectrophotometer
(NanoDrop, Wilmington, DE, USA), and the integrity and size
distribution of the purified RNA was determined by denaturing
agarose gel electrophoresis and ethidium bromide staining. The
quality of total RNA was further analyzed using the Agilent 2100
Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA), which
showed the good quality and integrity of the RNA samples (Data
not shown).
cDNA synthesis and labeling, microarray slide (Ocimum
Biosolutions) hybridization, Data collection and normalization,
and statistical analysis were performed as described in a
previous publication [71]. For each type of treatment
(0.06 mg / m lf o r1 . 5 h o u r so r1 . 2 5 mg/ml for 30 min), six
microarray slides were hybridized with RNA samples prepared
from 6 independent experiments. For this study, we chose p-
value,0.05 and the change $1.5-fold as the cutoff for
significant differential expression between the treated and
non-treated samples. Representative genes identified by the
DNA microarray were further confirmed by qRT-PCR as
described in a previous work [72]. The primers used for qRT-
PCR are listed in Table 2.
Insertional mutation of mfd
An isogenic mfd (cj1085c) mutant of strain NCTC 11168 was
constructed by insertional mutagenesis. Primers mfd-F2 (59-
TGTTGATGGAGAGTTAAGTGGTAT-39)a n dm f d - R 2( 5 9-
AATAGCATTCATAGCGACTTCTGTT-39)w e r ed e s i g n e d
from the published genomic sequence of this strain [48] and
used to amplify a 1.8-kb fragment spanning the 59 region of mfd.
Amplification was performed with Pfu Turbo DNA Polymerase
(Stratagene, La Jolla, CA, USA). The blunt-ended PCR product
was purified using a QIAquick PCR purification kit (Qiagen,
Valencia, CA, USA), ligated to SmaI–digested suicide vector
pUC19, resulting in the construction of pUC-mfd, which was
then transformed into E. coli DH5a. Since a unique EcoRVs i t e
(which generates blunt ends) occurs in the cloned mfd fragment,
pUC-mfd was digested with EcoRV to interrupt the mfd gene.
Primers KanNco-F (59 CTT ATC AAT ATA TCC ATG GAA
TGG GCA AAG CAT 39)a n dK a n N c o - R( 5 9 GAT AGA ACC
ATG GAT AAT GCT AAG ACA ATC ACT AAA 39)w e r e
used to amplify the aphA3 gene (encoding kanamycin resistance)
from the pMW10 vector [73] by using Pfu Turbo DNA
polymerase (Stratagene). The aphA3 PCR product was directly
Table 2. Oligonucleotide primers used in qRT-PCR.
Primer Sequence
Gene
amplified
16s RNA F 59-TAC CTG GGC TTG ATA TCC TA-39 16s RNA
16s RNA R 59-GGA CTT AAC CCA ACA TCT CA-39 cj0123c
Cj0123cF 59 CGC CTT GAT CTT TGT AGT GTT TT 39
Cj0123cR 59 TGA AAT CAA AAG CGG TAA AAG TG 39
Cj0824F1 59-CAA AGT GCG TCA CAA TGC TT-39 cj0824 (uppS)
Cj0824R1 59-GAT TTA TCG CGC TTG GAA GA-39
Cj1351F1 59-ATC CCC TTG GCA TTA GCT CT-39 cj1351 (pldA)
Cj1351R1 59-TGG AAT TTC GCC TCA CTA TT-39
Cj1264cF1 59-GCT TAG GCG TTC ATC TTT GC-39 cj1264c
Cj1264cR1 59-CAA AGC CAA AGT TCC ACC AT-39
Cj1085cF1 59-TGT TTT GCA AAC TCC ACC AG-3 cj1085c (mfd)
Cj1085cR1 59-ATT TTG CCC ACC ACG TCT TA-39
Cj0205F1 59-GAA AAG TTG CGG CTG AGT TT-39 cj0205 (uppP)
Cj0205R1 59-AAT TTG CAT TGC CAA GAA GC-39
Cj0537F1 59-GGC AAT TGG TGG AAA TCA TAC TA-39 cj0537
Cj0537R1 59-TGG AGT AGT TGG AGA AGT TTG AGA-39 cj0718(dnaE)
Cj0718F 59 GGACTTGGGGCTATAAAAAGTGT 39
Cj0718R 59 GGACTTGGGGCTATAAAAAGTGT 39
Cj1688cF1 59-GCC TGA ATT GAT TTG TCC TAC AG-39 cj1688c (secY)
Cj1688cR1 59-CGA ACA AAT CAC ACA AAG AGG TA-39
Cj0764cF1 59-TTC AGC TGC AAT AAA GCC TAT GT-39 cj0764c (speA)
Cj0764cR1 59-ATA ATA ACG AAG GCG CAC CTA TT-39
Cj1566cF1 59-CAT AAA TTT ACC CCA AAA CAC TCC-39 cj1566c
Cj1566cR1 59-GAG AGT TTA AAT GGG CTT TTG GT-39
doi:10.1371/journal.ppat.1000083.t002
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mfd-aphA3, in which the aphA3 gene was inserted within mfd (the
same direction as the transcription of mfd) and the insertion was
confirmed by PCR using primers mfd-F2 and Kana-intra (59
GAA GAA CAG TAT GTC GAG CTA TTT TTT GAC TTA
39). The pUC-mfd-aphA3 construct, which served as a suicide
vector, was electroporated into C. jejuni NCTC 11168. Trans-
formants were selected on MH agar containing 10 mg/ml of
kanamycin. Inactivation of the mfd gene in the transformants by
insertion of the ahpA3 gene was confirmed by PCR using primers
mfd-F2 and mfd-R2 (Fig. 1B). The mfd mutant of NCTC 11168
was named JH01.
Complementation of the mfd mutant in trans
The entire mfd gene including its putative ribosome binding
site was amplified from strain 11168 by PCR using primers mfd-
F5 (59-CGCTTCCGCGGAACTAGTAAAATTAAAGAAGA-
TACTATC-39)a n dm f d - R 3( 5 9-GGCTTTAAATAATCTTT
TCGAGCTCTATAAATT-39). The underlined sequences in the
primers indicate the restriction sites for SacIa n dSacII,
respectively. The PCR product was digested with SacIa n dSacII,
and was then cloned into the plasmid construct pRY112-pABC
to generate pRY112-mfd, in which the mfd gene was fused to the
promoter of cmeABC. pRY112-pABC was made by cloning the
promoter sequence of cmeABC [74] to shuttle plasmid pRY112
[75]. The promoter DNA of cmeABC was amplified by primers
BSF (59 AAAAGGATCCTAAATGGAATCAATAG 39)a n d
AR2 (59 TGATCTAGATCATACCGAGA 39), digested with
BamHI and XbaI, and cloned into pRY112. There were two
reasons that we used the promoter of cmeABC in the expression of
mfd.F i r s t ,t h e5 9 end of mfd overlaps with its upstream gene and
t h en a t i v ep r o m o t e rf o rmfd was unknown. Second, the promoter
of cmeABC is moderately active in Campylobacter [74], preventing
over- or under-expression of mfd. The constructed plasmid
pRY112-mfd was sequenced and confirmed that no mutations in
the cloned sequence occurred. For complementation, the shuttle
plasmid pRY112-mfd was transferred into JH01 by conjugation.
The complemented strain was named JH02. Limited passage of
JH02 in MH broth without antibiotics indicated that the
complementing plasmid was stable in the construct (data not
shown). The shuttle plasmid carrying the mfd gene was also
transferred to wild-type 11168 to generate strain JH03 for
overexpression of the mfd gene.
Growth rates in MH broth with or without CIPRO
To compare the growth kinetics of the mfd mutant with that of
the wild-type, a fresh culture of each strain was inoculated into
MH broth (initial cell density of OD600=0.05) and the cultures
were incubated at 42uC under microaerobic conditions. To
determine if the mutation affects C. jejuni growth with a
subinhibitory concentration of CIPRO, the various strains were
grown in MH broth with 0.06 mg/ml of CIPRO (0.56the MIC).
Culture samples were collected and measured for OD600 at 0, 3, 6,
12, 24 and 48 hours post-inoculation.
Antibiotic susceptibility test
The minimum inhibitory concentration (MIC) of CIPRO was
determined by using E-test strips (AB Biodisk, Solna, Sweden) as
described in the manufacturer’s instructions. The detection limit of
the E-test for CIPRO was 32 mg/ml. The MICs of erythromycin,
ampicillin and streptomycin for C. jejuni NCTC 11168, JH01,
JH02, and JH03 were determined using a standard microtiter
broth dilution method described previously [24]. Each MIC test
was repeated at least three times to confirm the reproducibility of
the MIC patterns. The antibiotics used in this study were
purchased from Sigma Chemical Co. (erythromycin, ampicillin,
streptomycin) or ICN Biomedicals Inc. (CIPRO).
Frequencies of emergence of spontaneous FQ
R mutants
in vitro
Wild-type 11168, JH01, JH02 and JH03 were compared for
the spontaneous mutation rates to CIPRO resistance. In each
experiment, each of the 4 strains was inoculated into three flasks,
each of which contained 30 ml of antibiotic-free MH broth. The
cultures were incubated to the mid logarithmic phase
(OD600<0.15) under microaerobic conditions. The culture in
each flask was collected by centrifugation and resuspended in
1 ml of MH broth. The total CFU in each culture was measured
by serial dilutions and plating on MH agar plates, while the
number of FQ
R mutants was detected using MH agar plates
containing 1, 2 or 4 mg/ml CIPRO. The frequency of
emergence of FQ
R mutants was calculated as the ratio of the
CFU on CIPRO-containing MH agar plates to the CFU on
antibiotic-free MH agar plates after 2 days of incubation at 42uC
under microaerobic conditions. This experiment was repeated
five times. The mutation frequency data were log-transformed
for statistical analysis. One-Way ANOVA followed by Tukey test
was used to determine the significance of differences in the levels
of spontaneous mutation rates among the strains. The data were
also analyzed by the Wilcoxon rank-sum test to allow for non-
normality. For the comparisons discussed in Results, the
conclusion of the two tests was the same at significance level
0.05.
Sequence analysis of the QRDR of gyrA
Representative FQ
R colonies were selected for determination of
the point mutations in gyrA. The QRDR of gyrA was amplified by
PCR using primer pair GyrAF1 (59-CAACTGGTTC-
TAGCCTTTTG-39) and GyrAR1 (59-AATTTCACTCA-
TAGCCTCACG-39) [76]. The amplified PCR products were
purified with the QIAquick PCR purification kit (Qiagen) prior to
sequence determination. DNA sequence analysis was carried out
using an automated ABI Prism 377 sequencer (Applied Biosys-
tems, Foster City, CA, USA) and analyzed by the Omiga 2.0
(Oxford Molecular Group) sequencing analysis software.
In vitro treatment with CIPRO
To determine if Mfd affects the development of FQ
R mutants
under treatment with CIPRO, wild-type 11168 and JH01 were
treated in MH broth with 4 mg/ml (326 the MIC) of CIPRO.
Wild-type 11168 and JH01 were grown on antibiotic-free MH
agar plates under microaerobic conditions. After 20 hours of
incubation, the cells were collected and resuspended in MH
broth for inoculation. Three treatment experiments were
conducted using three different initial cell densities. In
experiment 1, each strain was inoculated into 3 100-ml flasks
with MH broth containing 4 mg/ml of CIPRO and the initial
cell density was 10
7 CFU/ml. The cultures were incubated
microaerobically at 42uC. Aliquots of the cultures were collected
a td i f f e r e n tt i m ep o i n t s( 0 ,1 ,2 ,3d a y sp o s t - i n o c u l a t i o n )a n d
plated onto regular MH plates for enumeration of the total
bacterial number and onto MH plates containing 4 mg/ml of
CIPRO for counting FQ
R colonies. In experiments 2 and 3, the
cultures were treated in the same way, but the initial cell
densities were 10
6 and 10
3 CFU/ml, respectively. Experiment 1
was repeated three times, while experiments 2 and 3 were each
repeated twice.
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To determine if the insertional mutation in mfd affected the
expression of the downstream gene Cj1084c (encoding a possible
ATP/GTP-binding protein), RT-PCR was performed to assess the
expression of Cj1084c. Total RNA was isolated from C. jejuni 11168
and JH01 using the RNeasy Kit (Qiagen). The purified RNA
samples were treated with On-Column DNase Digestion Kit
(Qiagen) followed by further treatments with DNase to remove
DNA contamination. The Cj1084c-specific primers Cj1084cF (59
TTG CCT TAG CAG ATA TCA T 39) and Cj1084cR (59 ACC
ACT TCT ACT TGC TCT TA 39) were used to amplify a
430 bp region of the gene in a conventional one-step RT-PCR by
using the SuperScript III One-Step RT-PCR kit (Invitrogen). An
RT-PCR mixture lacking the RT was included as a negative
control.
Emergence of FQ
R mutants in enrofloxacin-treated
chickens
To examine if Mfd plays a role in the emergence of FQ
R
Campylobacter during in vivo FQ treatment, a chicken experiment
was performed using 11168 and JH01. Day-old broiler chickens
(Ross6Cobb) were obtained from a commercial hatchery and
randomly assigned to 2 groups (11 birds per group). Each group of
chickens was maintained in a sanitized wire-floored cage. Feed
and water were provided ad libitum. Prior to inoculation with
Campylobacter, the birds were tested negative for Campylobacter by
culturing cloacal swabs. At day 3 of age, the two groups of
chickens were inoculated with 11168 and JH01, respectively, at a
dose of 10
6 CFU/chick via oral gavage. Six days after the
inoculation, the birds were treated with 50 ppm enrofloxacin. The
treatment was administered in drinking water and lasted for five
consecutive days. During the treatment, only medicated water was
given to the birds to ensure enough consumption. Cloacal swabs
were collected periodically before and after enrofloxacin treatment
until the end of the experiment. Each swab was serially diluted in
MH broth and plated onto two different types of MH plates: one
containing Campylobacter-specific growth supplements (SR 084E
and SR117 E; Oxoid Ltd., Basingstoke, England) for the
enumeration of total Campylobacter cells and the other containing
4 mg/ml of CIPRO in addition to the same selective agents and
supplements to recover FQ
R Campylobacter in each chicken. At each
sampling time, at least one Campylobacter colony from each chicken
were selected from the regular MH agar plates (no CIPRO) for the
determination of CIPRO MICs using the E-test (AB Biodisk). The
colonization data (CFU/g feces) were log-transformed and used
for statistical analysis. The significance of differences in the level of
colonization between the two groups was determined using
Student’s t-test, Welch’s t-test to allow for non-constant variation
across treatment groups, and the Wilcoxon rank-sum test to allow
for non-normality. The conclusion of all three tests was the same at
significance level 0.05.
Microarray data accession number
The microarray data have been deposited in the NCBI Gene
Expression Omnibus (GEO; http://www.ncbi.nlm.nih.gov/geo/)
database and the accession number is GSE10471.
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